Plattsburgh,
NY, USA -- Monaghan Medical Corporation (MMC) today announced
results from a real-world study, evaluating the efficacy of the
Aerobika®
device in reducing chronic obstructive pulmonary disease (COPD)
exacerbations. These results were presented at the European
Respiratory Society International Congress in London, and are
anticipated to impact the future management of COPD patients with a
history of exacerbations.
Exacerbations
are a worsening of symptoms and are the most common reason for COPD
hospital admissions (1). During an exacerbation, airways are
compromised by inflammation and mucus buildup, causing patients to be
poorly responsive to usual COPD treatments (2). Recovery can be
delayed for weeks, resulting in further airway deterioration and
putting patients at risk of recurrent exacerbations. In fact,
approximately 1 in 5 admitted patients required re-hospitalization
within 30 days (3).
Clinicians,
hospitals, and healthcare systems around the globe are now focusing
their attention on this critical post-exacerbation period with the
goal of reducing subsequent re-admissions and maintaining the
long-term health of their COPD patients.
In
the 6-month study, the Aerobika®
device demonstrated a clinically-significant reduction in
exacerbations in as little as 30 days of treatment, when used as an
add-on to usual COPD medications. "These results carry important
implications for how we manage COPD patients with a history of
exacerbations," says Brian Carlin, MD, FCCP, FAASM. "Adding
the Aerobika®
device to our current COPD treatment protocols could significantly
improve patient outcomes while decreasing the burden on our
healthcare resources."
The
Aerobika®
device has been previously validated in clinical studies,
demonstrating improvements in airway ventilation, lung function and
quality of life. "This new study has validated the use of this
device in a real-world setting, providing a drug-free addition to
post-exacerbation therapy for COPD patients." says Dr. Jason
Suggett, Group Director of Science & Technology at Trudell
Medical International (TMI), the sister company for MMC.
About
the Aerobika®
device study
The
study profiled here is a 6-month retrospective cohort study of the
hospital Charge Detail Master (CDM) claims database, conducted
between September 2013 and August 2015. This real-word study involved
810 patients, 405 receiving treatment with the Aerobika®
device and 405 propensity score matched controls. The primary outcome
was the proportion of patients with moderate-to-severe and severe
exacerbations at 30 days. Secondary measures included resource
utilization and costs associated with exacerbations.
About
The Aerobika®
Device
The
Aerobika®
device is hand-held, easy-to-use, and drug-free. When the patient
exhales through the device, intermittent resistance creates positive
pressure and oscillations simultaneously, which stents open the
airways, mobilizes and assists in moving mucus to the upper airways
where it can be coughed out. This may also aid in improved drug
deposition. The Aerobika®
device is available in Canada, Mexico, and select European countries
including the UK and Germany through TMI and in the US via Monaghan
Medical Corporation. (http://www.monaghanmed.com/Aerobika)
About
Monaghan
Medical Corporation (MMC, USA)
MMC,
an affiliate of TMI, offers leading aerosol drug delivery devices and
respiratory management products including AeroEclipse®
II BAN, AeroChamber Plus® brand aVHC, and the
Aerobika®
device exclusively in the United States. Our strength lies in product
development around core capabilities in mechanical design
complimented by collaboration with a state-of-the-art aerosol
research laboratory. We focus on developing cost-efficient,
outcome-based solutions for our customers.
TMI
designs, develops and manufactures a wide range of medical devices
and is home to a global aerosol lab and research center. From the
flagship AeroChamber® Brand of Valved Holding Chamber
(VHC) and the latest award-winning Aerobika®
device, to custom designed products and systems, our best-in-class
respiratory management products are sold in over 110 countries. Their
efficacy has been validated in hundreds of peer-reviewed articles
from various medical journals.
References:
[1]
O'Donnell et al. Can Respir J. 2007;14(Suppl B):5B-32B.
[2]
O'Donnell DE, Parker CM. Thorax. 2006;61(4):354-61.
[3]
Shah et al. CHEST. 2016 May 7 [Epub ahead of print].
For
clinical inquiries, please contact:
Jason
Suggett, Group Director Science and Technology
Trudell
Medical International
519-455-7060
ext. 2270
